newsfilter
← Latest News
GlobeNewswire·

Mesoblast Board Changes

NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of